Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation

Alessandro Mezzani, Piergiuseppe Agostoni, Alain Cohen-Solal, Ugo Corrà, Anna Jegier, Evangelia Kouidi, Sanja Mazic, Philippe Meurin, Massimo Piepoli, Attila Simon, Christophe Van Laethem and Luc Vanhees

European Journal of Cardiovascular Prevention & Rehabilitation 2009 16: 249
DOI: 10.1097/HJR.0b013e32832914c8

The online version of this article can be found at:
http://cpr.sagepub.com/content/16/3/249
Cardiopulmonary exercise testing (CPET) is a methodology that has profoundly affected the approach to patients' functional evaluation, linking performance and physiological parameters to the underlying metabolic substratum and providing highly reproducible exercise capacity descriptors. This study provides professionals with an up-to-date review of the rationale sustaining the use of CPET for functional evaluation of cardiac patients in both the clinical and research settings, describing parameters obtainable either from ramp incremental or step constant-power CPET and illustrating the wealth of information obtainable through an experienced use of this powerful tool. The choice of parameters to be measured will depend on the specific goals of functional evaluation in the individual patient, namely, exercise tolerance assessment, training prescription, treatment efficacy evaluation, and/or investigation of exercise-induced adaptations of the oxygen transport/utilization system. The full potentialities of CPET in the clinical and research setting still remain largely underused and strong efforts are recommended to promote a more widespread use of CPET in the functional evaluation of cardiac patients. Eur J Cardiovasc Prev Rehabil 16:249–267 © 2009 The European Society of Cardiology

European Journal of Cardiovascular Prevention and Rehabilitation 2009, 16:249–267

Keyword: anaerobic threshold, cardiac disease, cardiopulmonary exercise testing, critical power, functional evaluation, oxygen consumption, ventilation
Such a production of CO₂, in excess of that produced by aerobic metabolism (excess CO₂), makes the CO₂ production (VCO₂) versus VO₂ relationship become steeper. This has been labeled ‘anaerobic threshold’ or also ‘aerobic threshold’ or ‘first lactate turn point’, with some terminology disagreement in the scientific literature [8], and is a reliable index of aerobic fitness used for training prescription in both normal individuals and cardiac patients, especially for sustainable submaximal work [9,10]. Interindividual variance, exercise protocol (e.g. fast versus slow work rate increments, step versus ramp protocols) [11], blood sampling source (e.g. venous, capillary, arterial, arterialized) [12], and type of exercise (e.g. running, swimming, cycling, rowing, etc.) [13] can all affect blood lactate kinetics.

By measuring gas exchange modifications induced by metabolic changes at the mouth, the ‘ventilatory anaerobic threshold’ (VAT) can be determined analyzing the slope of the VCO₂ versus VO₂ (plotted on equal scales) relationship during ramp incremental exercise (V-slope method) [14], where VAT is the point of transition of the VCO₂ versus VO₂ slope from less than 1 (activation of aerobic metabolism alone) to greater than 1 (anaerobic plus aerobic metabolism) (Fig. 1, upper panel). Moreover, the excess CO₂ produced above VAT increases ventilatory drive, which keeps the ventilation (VE) versus VCO₂ relationship linear and the end-tidal CO₂ pressure (PETCO₂) value constant (i.e. the individual does not hyperventilate with respect to the volume of CO₂ metabolically produced). However, an inversion of the VE versus VO₂ relationship behavior (increase versus initial decrease, i.e. hyperventilation with respect to O₂) is observed above VAT; this makes both the VE versus VO₂ ratio and end-tidal O₂ pressure increase, in the presence of a still decreasing or constant VE/VCO₂ and PETCO₂. VAT is thus also identifiable with the nadir of the VE versus VO₂ relationship and with the point where end-tidal O₂ pressure begins to increase [2] (Fig. 1, lower panel). In the final phase of exercise, hyperventilation does occur also with respect to CO₂ (respiratory compensation point), making VE/VCO₂ increase and PETCO₂ decrease [15] (Fig. 1, lower panel). VAT is usually expressed as a VO₂ value relative to predicted maximal oxygen uptake (VO₂max), the lower limit of normality being 40% of predicted VO₂max [16]. In the vast majority of healthy individuals, VAT occurs at approximately 40–60% of VO₂max (Table 2); in trained endurance athletes, VAT can reach intensities as high as 80% of their VO₂max [23].

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Aims of cardiac patients functional evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproducible assessment of patient’s exercise capacity</td>
<td></td>
</tr>
<tr>
<td>Prescription of endurance training intensity</td>
<td></td>
</tr>
<tr>
<td>Evaluation of response to endurance training</td>
<td></td>
</tr>
<tr>
<td>Evaluation of response to therapeutic interventions (drugs, ventricular resynchronization, etc.) affecting exercise capacity</td>
<td></td>
</tr>
<tr>
<td>Evaluation of the O₂ transport and utilization system efficiency (ventilatory, hemodynamic, and metabolic components)</td>
<td></td>
</tr>
</tbody>
</table>

Finally, as treatment of the use of CPET for differentiation of cardiac versus pulmonary causes of dyspnea and/or impaired exercise capacity is not a specific goal of this report, readers interested in this topic are referred to previously published reviews [4], as are those interested in the use of CPET for prognostic stratification of patients with cardiac disease (in particular, CHF) [5].

Use of cardiopulmonary exercise testing for the evaluation of O₂ transport and utilization efficiency

Ventilatory anaerobic threshold

During incremental exercise, an energy requirement is reached above which blood lactate concentration increases at a progressively steeper rate [6]. This is because of anaerobic glycolysis activation, that occurs as the oxygen supply rate is not rapid enough to reoxidize cytosolic NADH + H⁺ [7]. Almost all of the H⁺ generated in the cell from lactic acid (La) dissociation is buffered by bicarbonate according to the following reaction:

\[ H^+ + La^- + HCO_3^- \rightleftharpoons H_2O + CO_2 + La^- \]

Such a production of CO₂, in excess of that produced by aerobic metabolism (excess CO₂), makes the CO₂ production (VCO₂) versus VO₂ relationship become steeper. This has been labeled ‘anaerobic threshold’ or also ‘aerobic threshold’ or ‘first lactate turn point’, with some terminology disagreement in the scientific literature [8], and is a reliable index of aerobic fitness used for training prescription in both normal individuals and cardiac patients, especially for sustainable submaximal work [9,10]. Interindividual variance, exercise protocol (e.g. fast versus slow work rate increments, step versus ramp protocols) [11], blood sampling source (e.g. venous, capillary, arterial, arterialized) [12], and type of exercise (e.g. running, swimming, cycling, rowing, etc.) [13] can all affect blood lactate kinetics.

By measuring gas exchange modifications induced by metabolic changes at the mouth, the ‘ventilatory anaerobic threshold’ (VAT) can be determined analyzing the slope of the VCO₂ versus VO₂ (plotted on equal scales) relationship during ramp incremental exercise (V-slope method) [14], where VAT is the point of transition of the VCO₂ versus VO₂ slope from less than 1 (activation of aerobic metabolism alone) to greater than 1 (anaerobic plus aerobic metabolism) (Fig. 1, upper panel). Moreover, the excess CO₂ produced above VAT increases ventilatory drive, which keeps the ventilation (VE) versus VCO₂ relationship linear and the end-tidal CO₂ pressure (PETCO₂) value constant (i.e. the individual does not hyperventilate with respect to the volume of CO₂ metabolically produced). However, an inversion of the VE versus VO₂ relationship behavior (increase versus initial decrease, i.e. hyperventilation with respect to O₂) is observed above VAT; this makes both the VE versus VO₂ ratio and end-tidal O₂ pressure increase, in the presence of a still decreasing or constant VE/VCO₂ and PETCO₂. VAT is thus also identifiable with the nadir of the VE versus VO₂ relationship and with the point where end-tidal O₂ pressure begins to increase [2] (Fig. 1, lower panel). In the final phase of exercise, hyperventilation does occur also with respect to CO₂ (respiratory compensation point), making VE/VCO₂ increase and PETCO₂ decrease [15] (Fig. 1, lower panel). VAT is usually expressed as a VO₂ value relative to predicted maximal oxygen uptake (VO₂max), the lower limit of normality being 40% of predicted VO₂max [16]. In the vast majority of healthy individuals, VAT occurs at approximately 40–60% of VO₂max (Table 2); in trained endurance athletes, VAT can reach intensities as high as 80% of their VO₂max [23].

All cardiac diseases affecting the O₂ transport chain (typically CHF) can determine a pathologic VAT (i.e. < 40% predicted VO₂max) [24], as can deconditioning following bed rest for cardiac events, even in the presence of normal left ventricular systolic function [25]. However, when expressed relative to measured peakVO₂ (and not to predicted VO₂max), VAT will still occur at approximately 40–60% of peakVO₂ in most cardiac patients, with a trend toward higher percentages of peakVO₂ in patients with CHF [7,16,24,26]. Notably, VAT may be not detectable in a variable percentage of patients [27], and especially in those with CHF because of exercise oscillatory VE and/or shortness of exercise time.
Maximal oxygen uptake

VO₂\text{max} is a parameter which describes the maximal amount of energy obtainable by aerobic metabolism per unit of time (aerobic power). VO₂ is defined by the Fick equation:

\[
\text{VO}_2 = \text{CO} \times C(a - v)\text{O}_2
\]

where CO is cardiac output and C(a − v)O₂ is the arteriovenous O₂ content difference. In healthy individuals, VO₂\text{max} is mostly limited by CO rather than by peripheral factors [28], its value, however, being influenced by several parameters, such as arterial O₂ content, fractional distribution of CO to exercising muscles, and muscle ability to extract O₂; recent data also indicate a possible role of a central nervous system governor [29]. VO₂\text{max} attainment is evidenced by failure of VO₂ to increase despite increasing work rate [30]. However, flattening of the VO₂ versus power relationship is not seen often in routine clinical practice, and therefore a more realistic goal is to assess peakVO₂ rather than VO₂\text{max}. PeakVO₂ is defined as the highest VO₂, averaged over a 20 to 30-s period, achieved at presumed maximal effort during an incremental exercise test, and may or may not be equal to VO₂\text{max}, even if available evidence suggests that these two concepts are substantially analogous [31]. In any case, peakVO₂ describes patients’ exercise tolerance far more reliably than exercise duration or peak power [32]. Achievement of truly maximal effort (and thus of reliable VO₂\text{max} values) can be assumed in the presence of one or more of the following criteria [33]:

1. Failure of VO₂ and/or heart rate to increase with further increases in work rate.
2. Peak respiratory exchange ratio (\(\text{VCO}_2/\text{VO}_2\)) ≥ 1.10–1.15.
3. Postexercise blood lactate concentration ≥ 8 mmol/dl.
4. Rating of perceived exertion ≥ 8 (on the 10-point Borg scale).

Normal values of VO₂\text{max} depend on age and sex, and are influenced by body size, level of physical activity, and genetic endowment [34]. VO₂\text{max} is measured in liters or milliliters of O₂ per minute, or in milliliters of O₂ per kilogram of body weight per minute. The highest values of VO₂\text{max} are reported in endurance athletes (94 ml/kg per min) [35]. VO₂\text{max} declines on average by 10% per decade after the age of 30, because of decreasing maximal heart rate, stroke volume, blood flow to skeletal muscle, and skeletal muscle aerobic potential with age [36]. VO₂\text{max} is also 10 to 20% greater in males than in females of comparable age [37], because of higher hemoglobin (Hb) concentration and greater muscle mass and stroke volume in males. Several formulae based on age and body dimensions are available for VO₂\text{max} prediction in sedentary men and women, the most detailed recommendation being provided by Wasserman et al. [16] (Table 2).

Many cardiovascular diseases can affect VO₂\text{max}/peakVO₂. Namely, all pathologies impairing CO response to exercise will determine some degree of reduction of peakVO₂ with respect to predicted VO₂\text{max}. For example, in patients with CHF peakVO₂ is classically reduced with respect to age-matched and sex-matched normal individuals [24], but is also lower than normal in patients with preserved left ventricular function entering a rehabilitation program after recent cardiac surgery [38], because of...
Critical power

Critical power represents the highest power sustainable in conditions of both VO₂ and lactate steady state [17], overlapping, as such, the concept of maximal lactate steady state, that is, the highest power sustainable in conditions of stable blood lactate concentration [41]. As aerobic exercise is usually performed in steady-state conditions, the critical power is a crucial (though quite neglected) marker of the upper limit of sustainable aerobic training intensity [42], situated between VAT and peakVO₂ powers as assessed during ramp incremental CPET.

From a mathematical standpoint, critical power corresponds to the power asymptote of the hyperbolic relationship linking power and duration of the constant-power exercise [17]. The determination of critical power requires the performance of four to five constant-power exercise tests in the above-VAT threshold effort intensity domains (see section VO₂ on-kinetics), with relative intensities ranging between 70 and 120% of peak power reached during an incremental ramp exercise test [17]; the critical power is then obtained by fitting a rectangular hyperbola on the obtained power versus duration points (Fig. 2). Such a procedure is of course not feasible in the routine clinical setting; however, the existence of a very close correlation between critical power and power at respiratory compensation point during ramp incremental CPET has been described [43]. If these data were confirmed, a single and easy-to-perform test, CPET, would provide operators with all the parameters describing O₂ transport and utilization system efficiency descriptors, critical anaerobic threshold, critical power, and peakVO₂.

Critical power has been evaluated by several authors in sedentary young normal individuals, revealing repeatable values around 65–70% of peak power (or 25–30% of ΔVAT−peakVO₂ power) (Table 2) at incremental exercise testing, with a steady-state VO₂ mean value corresponding to 70–80% of peakVO₂ [17,42]. Elderly individuals show critical power values similar to those of young individuals when expressed relative to peak power, but with higher relative steady-state VO₂ values (approximately 80–90% of peakVO₂), demonstrating a broadening of the high-intensity domain of effort, probably aimed at preservation of habitual activities performance in steady-state, nonfatiguing metabolic conditions [44]. Notably, similar to the other O₂ transport and utilization system efficiency descriptors, critical power is also increased by aerobic training [45].

Table 2  Normal values

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal values</th>
<th>Formule</th>
</tr>
</thead>
<tbody>
<tr>
<td>VO₂ at VAT (ml/min) [16]</td>
<td>&gt;40% predicted VO₂max 40–60% peakVO₂</td>
<td>–</td>
</tr>
<tr>
<td>Critical power (W) [17]</td>
<td>65–70% of peak power, 25–30% of ΔVAT−peak power</td>
<td>–</td>
</tr>
<tr>
<td>VO₂max (ml/min) [16]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Age (years)</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>20</td>
<td>3246 (43.3)</td>
<td>1996 (33.3)</td>
</tr>
<tr>
<td>30</td>
<td>2967 (39.6)</td>
<td>1821 (30.3)</td>
</tr>
<tr>
<td>40</td>
<td>2699 (35.8)</td>
<td>1648 (27.4)</td>
</tr>
<tr>
<td>50</td>
<td>2409 (32.1)</td>
<td>1471 (24.5)</td>
</tr>
<tr>
<td>60</td>
<td>2130 (28.4)</td>
<td>1296 (21.6)</td>
</tr>
<tr>
<td>70</td>
<td>1851 (24.7)</td>
<td>1121 (18.7)</td>
</tr>
<tr>
<td>80</td>
<td>1572 (21.0)</td>
<td>945 (15.7)</td>
</tr>
<tr>
<td>VO₂ on-kinetics mean response time (s) [18]</td>
<td>30–44</td>
<td>34–43</td>
</tr>
<tr>
<td>45–59</td>
<td>44–53</td>
<td>–</td>
</tr>
<tr>
<td>60–80</td>
<td>54–67</td>
<td>(0.67 × age) + 13.9</td>
</tr>
<tr>
<td>VO₂ off-kinetics T₁/2 (s) [19]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>50–59</td>
<td>2647–2407</td>
<td>1773–1830</td>
</tr>
<tr>
<td>60–69</td>
<td>2380–2140</td>
<td>1615–1472</td>
</tr>
<tr>
<td>70–80</td>
<td>2113–1846</td>
<td>1457–1300</td>
</tr>
<tr>
<td>VE versus VCO₂ slope [21]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>20–39</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>20–39</td>
<td>23.4–25.7</td>
<td>26.8–28.3</td>
</tr>
<tr>
<td>40–59</td>
<td>25.8–28.1</td>
<td>28.4–29.9</td>
</tr>
<tr>
<td>60–80</td>
<td>28.2–30.6</td>
<td>30.0–31.6</td>
</tr>
</tbody>
</table>

BSA, body surface area; F, females; M, males; peakVO₂, peak oxygen consumption; T₁/2, time necessary for VO₂ to decrease by 50% from its peak effort value; VAT, ventilatory anaerobic threshold; VO₂max, maximal oxygen uptake. Values are calculated for men of 75 kg and women of 60 kg weight, values in brackets are ml/kg per min.

Critical power is then obtained by fitting a rectangular hyperbola on the obtained power versus duration points (Fig. 2). Such a procedure is of course not feasible in the routine clinical setting; however, the existence of a very close correlation between critical power and power at respiratory compensation point during ramp incremental CPET has been described [43]. If these data were confirmed, a single and easy-to-perform test, CPET, would provide operators with all the parameters describing O₂ transport and utilization system efficiency, that is, anaerobic threshold, critical power, and peakVO₂.

Critical power has been evaluated by several authors in sedentary young normal individuals, revealing repeatable values around 65–70% of peak power (or 25–30% of ΔVAT−peakVO₂ power) (Table 2) at incremental exercise testing, with a steady-state VO₂ mean value corresponding to 70–80% of peakVO₂ [17,42]. Elderly individuals show critical power values similar to those of young individuals when expressed relative to peak power, but with higher relative steady-state VO₂ values (approximately 80–90% of peakVO₂), demonstrating a broadening of the high-intensity domain of effort, probably aimed at preservation of habitual activities performance in steady-state, nonfatiguing metabolic conditions [44]. Notably, similar to the other O₂ transport and utilization system efficiency descriptors, critical power is also increased by aerobic training [45].

From a mathematical standpoint, critical power corresponds to the power asymptote of the hyperbolic relationship linking power and duration of the constant-power exercise [17]. The determination of critical power requires the performance of four to five constant-power exercise tests in the above-VAT threshold effort intensity domains (see section VO₂ on-kinetics), with relative intensities ranging between 70 and 120% of peak power reached during an incremental ramp exercise test [17]; the critical power is then obtained by fitting a rectangular hyperbola on the obtained power versus duration points (Fig. 2). Such a procedure is of course not feasible in the routine clinical setting; however, the existence of a very close correlation between critical power and power at respiratory compensation point during ramp incremental CPET has been described [43]. If these data were confirmed, a single and easy-to-perform test, CPET, would provide operators with all the parameters describing O₂ transport and utilization system efficiency, that is, anaerobic threshold, critical power, and peakVO₂.

Critical power has been evaluated by several authors in sedentary young normal individuals, revealing repeatable values around 65–70% of peak power (or 25–30% of ΔVAT−peakVO₂ power) (Table 2) at incremental exercise testing, with a steady-state VO₂ mean value corresponding to 70–80% of peakVO₂ [17,42]. Elderly individuals show critical power values similar to those of young individuals when expressed relative to peak power, but with higher relative steady-state VO₂ values (approximately 80–90% of peakVO₂), demonstrating a broadening of the high-intensity domain of effort, probably aimed at preservation of habitual activities performance in steady-state, nonfatiguing metabolic conditions [44]. Notably, similar to the other O₂ transport and utilization system efficiency descriptors, critical power is also increased by aerobic training [45].
VO₂ on-kinetics

During constant-power exercise below the anaerobic threshold (moderate-intensity effort domain), three phases of VO₂ on-kinetics are classically described in human physiology [47–49]: phase I, during which the VO₂ increase would rely mostly on pulmonary blood flow (i.e., CO) increment in the presence of an unchanging C(a-v)O₂; phase II, characterized by a monoexponential VO₂ increase mainly reflecting skeletal muscle VO₂ consumption, as described by C(a-v)O₂ widening; and phase III, that is, steady-state attainment (Fig. 3). As VO₂ does not reach instantaneously its steady-state value at step exercise onset, during phase I and phase II an O₂ deficit accumulates, defined as the cumulative difference between steady-state VO₂ level and VO₂ levels throughout the whole on-response (Fig. 3); the O₂ deficit will be larger the greater the recourse to anaerobic energy sources (alactic and lactic) and body O₂ stores before steady-state attainment [49,50]. Above anaerobic threshold and up to critical power (high-intensity effort domain), it is still possible to reach a VO₂ steady state for constant-power efforts (see section ‘Critical power’), even if in this intensity domain an additional, delayed-onset VO₂ component (‘slow component’) adds to the expected steady-state VO₂ value according to the below-VAT VO₂ versus power relationship [49,51,52]. The latter can be determined either by performing multiple constant-power exercise tests at different below-VAT powers and then fitting a linear relationship on the obtained VO₂ versus power points, or with an incremental ramp CPET, by fitting a linear function to the breath-by-breath below-VAT VO₂ versus power data, excluding from the fitting window the initial nonincreasing or poorly increasing VO₂ period [53,54]; the VO₂ versus power slope values obtained with the above two methods have been shown to be superimposable [54]. Beyond critical power (very high-intensity effort domain), a steady state is no longer attainable, and the VO₂ slow component makes VO₂ increase inexorably up to VO₂max [49,51,52].

The presence of the VO₂ slow component introduces some methodological caveats about VO₂ on-response evaluation in the high-intensity and very-high-intensity domains [51,52]; for this reason, VO₂ on-kinetics is more easily assessed during moderate-intensity effort, and can thus be evaluated also in individuals unable to exercise maximally. In this context, phase I is described in terms of its amplitude and duration, whereas the monoexponential VO₂ increase during phase II through its time constant (i.e. the time needed to reach 63% of the steady-state value), fitted on the VO₂ data starting from the phase I to phase II transition [49] (Fig. 3).

VO₂ on-kinetics in the moderate-intensity effort domain becomes more prolonged with age (Table 2), as demonstrated by increasing values of both its mean response time (i.e. the time constant of the whole VO₂ on-response, involving both phase I and phase II, fitted on the VO₂ data from time=0 of the exercise phase, see Fig. 3) [18] and phase II time constant [55], which is because of modifications of the O₂ transport and utilization system during the aging process described in the section ‘Maximal oxygen uptake’. Moreover, aerobic training affects the VO₂ on-kinetics similarly to the other descriptors of aerobic performance efficiency by shortening both the mean response time and the phase II time constant [56], that is, making the system adapt more rapidly to changes of loading conditions.

Cardiac disease can affect VO₂ on-kinetics in the moderate-intensity effort domain mainly by reducing O₂ delivery to exercising skeletal muscles. This is evidenced by a prolonged mean response time in patients with coronary artery disease and lone atrial fibrillation with respect to normal individuals [57,58], and is confirmed by the finding of improved VO₂ on-kinetics after percutaneous transluminal coronary angioplasty [59]. A significant prolongation of mean response time is also observed in patients with CHF [60], whose pathophysiology affects several steps of the O₂ transport/utilization system (see section ‘Patients with chronic heart failure’), whereas a
shortening of mean response time is observed in these patients after left ventricular assist device implantation [61].

**VO₂ off-kinetics**

During the resting recovery phase after constant-power moderate-intensity exercise, the O₂ debt contracted during the O₂ deficit accumulation is paid by a VO₂ in excess of the resting level (Fig. 3) [7,62]; the same phenomenon is observed during recovery from an incremental exercise test. Such an O₂ uptake is necessary for the rephosphorylation of creatine in skeletal muscles and, later, conversion of lactate to pyruvate and other mechanisms [63,64]. VO₂ during recovery fits an exponential function, and can be described by the time constant of the VO₂ off-response or its T₁/₂, that is, the time necessary for VO₂ to decrease by 50% from its peak effort value [19]. The more efficient the O₂ delivery to, and O₂ utilization by, exercising skeletal muscles, the faster this time is; hence, it is shorter in athletes and longer in deconditioned patients [65].

After an incremental ramp exercise test, the average T₁/₂ value in normal individuals ranges between 60 and 90 s (Table 2), and would seem to become more prolonged with advancing age, although no conclusive data are available on age-induced VO₂ off-kinetics modifications [19,66,67]. T₁/₂ is largely independent of exercise intensity, at least as long as it remains greater that 75% of the maximum [19]; this can be particularly interesting in individuals who stop exercising before peak effort because of symptoms, poor motivation, or fear and in whom peakVO₂ is underestimated. Thus, a low peakVO₂ in the presence of normal VO₂ recovery kinetics suggests submaximal effort; conversely, a long T₁/₂ reinforces the value of a low peakVO₂.

All pathologies affecting the O₂ transport chain from ambient air to exercising skeletal muscle are expected to influence the postexercise VO₂ behavior. Indeed, several authors have shown that the kinetics of VO₂ recovery both after the constant-power and the incremental exercise testing are slowed in patients with congenital
heart disease and CHF [19,66–69]; data for post-myocardial infarction patients are less clear [70,71].

**Use of cardiopulmonary exercise testing for the evaluation of ventilation efficiency and control**

**VO₂ versus ventilation relationship: the oxygen uptake efficiency slope**

The oxygen uptake efficiency slope (OUES) represents the rate of increase of VO₂ in response to a given VE during incremental exercise, indicating how effectively oxygen is extracted and taken into the body [72]. OUES is mainly influenced by the onset of lactic acidosis (which depends on the distribution of blood to the working muscles), muscle mass, oxygen extraction and utilization, and the physiologic pulmonary dead space (which in turn is affected by lung perfusion and structural integrity), thus incorporating cardiovascular, musculoskeletal, and respiratory function into a single index.

OUES is determined from the linear relation of VO₂ (y-axis) versus the logarithm of VE (x-axis) during exercise, that is, \( VO₂ = a \log_{10} VE + b \), where ‘a’ is the OUES and ‘b’ is the intercept [72] (Fig. 4, upper panel). The logarithmic transformation of VE is aimed at linearizing the otherwise curvilinear relation of VO₂ versus VE, thus making the OUES theoretically independent of the patient-achieved effort level. Several studies have tested this hypothesis [20,72–79], showing either equal or slightly higher or lower submaximal versus maximal OUES values, which thus outweigh the substantially larger differences in peakVO₂ measurements observed in the case of premature termination of the exercise test. The feasibility and repeatability of OUES determination is superior to that of VAT [20,73–76,79–81], and is easily calculated by a simple mathematical formula, thus improving intraobserver and interobserver measurement variability and objectivity [82]. In healthy individuals, OUES has been investigated in children [72] and adults [20,74,77]. Age-adjusted OUES values can be predicted using the sex-specific equations by Hollenberg and Tager [20] (Table 2).

In patients with coronary artery disease, OUES is significantly reduced [75,79,81]. However, patients who have undergone percutaneous transluminal coronary angioplasty with or without prior myocardial infarction have significantly higher OUES values compared with patients after coronary artery bypass grafting [79]. This may be explained by a higher disease severity, preoperative and postoperative deconditioning, and the impact of chest surgery on lung perfusion and structural integrity in the latter group. Furthermore, OUES is impaired in coronary artery disease patients with atrial fibrillation as compared with those in normal sinus rhythm [79]; this is likely because of the impact of decreased oxygen delivery on the working muscles in patients with atrial fibrillation, owing to lower stroke volume and CO response during exercise [83]. In CHF, the OUES is reduced in proportion to disease severity [20,75,76,81] (see section ‘Patients with chronic heart failure’ and Fig. 4, upper panel).

Physical training has been shown to increase OUES in both coronary artery disease and CHF patients [79,81], suggesting that, after training, a given oxygen uptake is achieved with a lower ventilatory cost. This OUES increase may be because of a reduced metabolic acidosis and/or ventilatory response at submaximal effort intensities. The training-induced changes of OUES parallel those of peakVO₂ [79,81], showing that OUES is sensitive to improvements in exercise tolerance. OUES would therefore seem to be clinically useful to monitor changes in exercise performance and effects of physical training, particularly in patients who can only perform submaximal exercise.

**Ventilation versus VCO₂ relationship: the VE versus VCO₂ slope**

Despite a manifold increase in VCO₂ and VO₂ during incremental exercise, the ventilatory control mechanisms normally keep arterial CO₂ tension (PaCO₂) and pH remarkably constant over a wide range of metabolic rates. The slope of the relationship between VE and VCO₂ describes the ventilatory efficiency during effort, showing the amount of air that must be ventilated to eliminate 11 of CO₂ (Fig. 4, lower panel). The basic information given by the VE versus VCO₂ slope is incorporated in the modified alveolar equation [84]:

\[
VE = 863 \times \frac{V_{CO₂}}{PaCO₂} \times (1 - \frac{V_D}{V_T})
\]

where \( V_D \) and \( V_T \) are volume of pulmonary dead space and tidal volume, respectively.

If \( PaCO₂ \) is driven down by a high ventilatory drive from peripheral chemoreceptors and/or \( V_D/V_T \) is high, the VE versus VCO₂ slope increases; a low \( V_T \) with respect to a normal anatomic dead space and/or an abnormally high physiological dead space are potential sources of high \( V_D/V_T \) [85]. Another proposed cause of increased ventilatory drive during exercise is effort-induced muscle metaboreflex (ergoreflex) overactivation [86]. Notably, during incremental exercise VE and VCO₂ are linearly related until VE increases disproportionately to VCO₂ (respiratory compensation point, see section ‘Ventilatory anaerobic threshold’). There is still controversy about whether the VE versus VCO₂ slope should be calculated across the overall exercise data or only up to the respiratory compensation point; although its assessment until this point is the logical one from a physiological standpoint, calculation over the whole exercise period seems to
increase the VE versus VCO₂ slope prognostic value in CHF patients [87].

Normal values of the VE versus VCO₂ slope range between 20 and 30, with an intercept on the VE axis of some 4–5 l/min because of a reduction of $V_D/V_T$ ratio after the start of exercise and/or early exercise hyperventilation. The VE versus VCO₂ slope is affected by age, showing increasing values with increasing age [21] (Table 2). A higher than normal VE versus VCO₂ slope may be of undeterminable origin (primary hyperventilation) or because of hypoxia or respiratory or cardiac diseases that can stimulate VE (secondary hyperventilation). Conversely, a downward displacement of the VE versus VCO₂ slope occurs when the PaCO₂ set point is raised, that is, in primary alveolar hypoventilation syndrome (impaired ventilatory chemoreflex function).

In patients with coronary artery disease (previous myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and significant chronic coronary stenosis), the VE versus VCO₂ slope has been shown to be higher the lower the peakVO₂ is [88]. This could be because of a marked sympathetic overactivity and neurohormonal imbalance in these patients, causing an exaggerated ventilatory response to exercise and/or to exercise-induced ischemia, causing a mismatch between CO response to exercise and increasing work rate and a consequent metabolic acidosis. The VE versus VCO₂ slope has been found to be increased also in patients with congenital heart disease, probably because of an altered $V_D/V_T$ ratio in this population [89,90]. Finally, a high VE versus VCO₂ slope is frequently observed in CHF patients (Fig. 4, lower panel) and is associated with the severity of disease [91–93] (see section ‘Patients with chronic heart failure’).

**Exercise oscillatory ventilation**

Periodic breathing oscillations of VO₂, VCO₂, and VE may be present in humans during spontaneous breathing while awake (both at rest and during exercise) and during sleep, and their presence is usually associated with an underlying pathological condition [94]. Exercise-induced oscillatory ventilation (EOV) is a slow, prominent, consistent (rather than random) fluctuation of VE during incremental exercise that may be evanescent or transient and has several distinct patterns. It has been observed throughout the entire exercise protocol, or only during early or peak exercise [95–98]. The origin of these oscillations is unclear, and several mechanisms have been proposed, which may be conveniently grouped into ventilatory (i.e. instability in the feedback ventilatory control system) and hemodynamic (i.e. pulmonary blood flow fluctuations) [99].

EOV has been defined in different ways. Kremser et al.’s [95] definition relies on the presence of cyclic fluctuations in VE lasting longer than 66% of the exercise protocol, with an amplitude of more than 15% of the average value at rest, and diminishing during heavy exercise (Fig. 5). Leite et al.’s [100] description is based on the following criteria: (i) three or more regular oscillations (i.e. clearly distinguishable from inherent data noise); (ii) regularity, so-defined when the standard deviation of three consecutive cycle lengths (time between two consecutive nadirs) is within 20% of the average; and (iii) minimal average amplitude of VE oscillation equals to 5 l (peak value minus the average of
two in-between consecutive nadirs). Notably, the detection of VAT is often masked by the presence of EOV [97].

Among cardiac patients, EOV during exercise testing has been specifically detected in those with CHF (see section ‘Patients with chronic heart failure’), and associated with cyclic changes in arterial O₂ and CO₂ tensions; the magnitude of EOV during exercise is correlated with the severity of heart failure [99].

Use of cardiopulmonary exercise testing for the evaluation of central hemodynamics

**VO₂ and cardiac output**

As already shown in the section ‘Maximal oxygen uptake’, VO₂ is the product of CO times C(a–v)O₂. In the systemic circulation, O₂ content increases during incremental exercise above VAT because of an increase in Hb, which is mainly because of the oncotic effect of increased intracellular lactate concentration [101,102]. In the pulmonary artery, O₂ content diminishes progressively throughout the entire exercise; below anaerobic threshold, this is because of a reduction of arterial O₂ tension (PaO₂) and above anaerobic threshold of both a shift in the oxyhemoglobin dissociation curve (Bohr effect) and a reduction of PaO₂ [103]. As a consequence, C(a–v)O₂ increases linearly with progression of work rate, and its value is relatively fixed at anaerobic threshold and peak effort in normal individuals, which makes C(a–v)O₂ at a given relative intensity of effort predictable, and CO indirectly assessable according to the Fick equation, when the corresponding absolute VO₂ value is known [104,105]. Alternatively, stroke volume at peak exercise can be estimated through the oxygen pulse, which is VO₂/heart rate, that is, stroke volume multiplied by C(a–v)O₂; assuming normal values of arterial O₂ content and C(a–v)O₂ at peak effort, peak stroke volume in milliliter can then be calculated as (peak oxygen pulse/15) × 100, where oxygen pulse is in milliliters per beat [30]; however, this estimation must be used with caution in nonperfectly normal and motivated individuals.

Few data are available as to normal CO values during effort. A frequently used formula based on the cardiac index versus VO₂ relationship during incremental exercise [106] has been adapted for CO estimation by converting cardiac index into CO values [22] (Table 2). This formula estimates the lower limit of normality for CO increase at a given VO₂ (i.e. energy expenditure) value in young to middle-aged healthy males.

In CHF patients, C(a–v)O₂ has a lower variability at VAT than at peak exercise, allowing more reliable CO estimates at such exercise intensity [107]. Indeed, estimated CO at VAT has been shown to independently predict multivessel coronary artery disease and the combined end point of cardiac death, reinfarction, and clinically driven revascularization in patients with recent acute myocardial infarction and reduced left ventricular ejection fraction [108]. However, rather than CO estimation during exercise, its direct noninvasive determination by means of CO₂ rebreathing or inert gas methods [109] together with VO₂ measurement might...
be a major advance in the evaluation of cardiac patients, allowing to calculate the $e^{-0.00001x}$ and to build the CO/C(a−v)O$_2$/VO$_2$ plot (Fig. 6) [110]. This plot helps to discriminate between exercise limitation because of altered left ventricle pump function or other causes, mainly muscle deconditioning; indeed, for corresponding VO$_2$ values, in the former case CO increase is limited in the presence of a maximal widening of the C(a−v)O$_2$, whereas in the latter CO increase is greater with a lesser widening of the C(a−v)O$_2$. This can be useful in CHF patients, in whom both a normal and reduced CO response during effort has been described in the presence of a reduced peakVO$_2$ [22,111,112]. Moreover, the role of anemia in functional capacity impairment can be precisely calculated as well [113]. As each Hb gram carries 1.34 ml of O$_2$, and as at peak exercise Hb desaturation is approximately 70%, each gram of Hb delivers to the muscle about 1 ml of O$_2$. In normal conditions, Hb is 15 g/dl, and, if peak CO (dl/min) is known, one can easily estimate the amount of missing VO$_2$ owing to anemia at peak effort. For example, if peak CO is 7.0 l/min, that is, 70 dl/min, and Hb is 10 g/dl, the amount of VO$_2$ lacking because of anemia is 15 (normal Hb) − 10 (observed Hb) × 70 = 350 ml/min. Such a calculation is possible only if patients are normoxic, have no cardiac shunt, and the exercise is performed at sea level. This information can be very useful when planning a training intervention in the cardiac rehabilitation setting.

**Circulatory power**

Circulatory power, the product of CO and central aortic (or mean arterial) pressure, is one of the most powerful indices of cardiac systolic function [114–116]. This is because the heart and proximal vascular system are closely coupled and for two similar CO responses to exercise or to any stress, the ability – as opposed to inability – to sustain an optimal pressure testifies to a higher efficiency of the cardiac pump. Indeed, it has been shown that an impaired blood pressure response during exercise is associated with cardiac dysfunction and poor outcome [117]. For cardiac pumping capability determination during effort, cardiac power can be assessed noninvasively by using the CO$_2$ rebreathing or inert gas methods to measure CO [118–121]. The ‘circulatory power’ is a cardiac power surrogate obtainable from CPET, calculated as peakVO$_2$ multiplied by peak systolic blood pressure [122]. As such, circulatory power represents the triple product of CO × C(a−v)O$_2$ (from the Fick equation) × systolic blood pressure. For circulatory power to closely estimate cardiac power, there should not be a great difference in C(a−v)O$_2$ at peak exercise in either normal individuals or cardiac patients, which is usually the case [104,105,123–125]. Moreover, systolic blood pressure and mean arterial pressure should increase in parallel during exercise. In any case, given the inconsistency of diastolic blood pressure manual recording during exercise, systolic blood pressure measurement is more reliable than mean blood pressure in a noninvasive laboratory setting. Finally, unlike invasive assessment of cardiac power, never possible at truly peak exercise, circulatory power can be easily assessed at maximal effort during incremental exercise testing.

The normal values of peak circulatory power have not been extensively assessed and, like peakVO$_2$, depend on age, sex, body mass, and training level. Considering 25–40 ml/kg per min as normal values for peakVO$_2$ and 150–220 mmHg for peak systolic blood pressure, normal values of peak circulatory power between 3500 and 8800 mmHg × ml/kg/min are obtained (Table 2), the highest being found in athletes and in hypertensive patients with preserved systolic function. Patients with CHF generally have values less than 3000 mmHg × ml/kg per min, and values less than 1800 mmHg × ml/kg per min seem to be associated with a very-high short-term risk requiring aggressive treatment, such as in the case of heart transplantation. Circulatory power can also be calculated expressing peakVO$_2$ as a percentage of predicted VO$_2$$_{\text{max}}$ [126].

Circulatory power is an interesting parameter for the functional evaluation of cardiac patients as it summarizes heart rate, stroke volume, blood pressure, and C(a−v)O$_2$ responses to exercise (all of which can be altered in several cardiac pathophysiological conditions, in particular...
CHF), although it does not allow to distinguish between them as to relative responsibility for the exercise capacity impairment. Vasodilators and β-blockers may alter peakVO₂ and systolic blood pressure in opposite ways, but the final interaction between drug therapy and circulatory power has not been thoroughly evaluated yet [127].

**Use of cardiopulmonary exercise testing for the evaluation of exercise relative intensity**

The VO₂ reserve (VO₂R) is the difference between resting and peakVO₂, and, as it describes the O₂ used during exercise in addition to basal consumption, is considered a direct measure of the exercise load or energy expenditure [128,129]. As a consequence, the percentage of VO₂R (%VO₂R) is now considered the gold standard for estimation, prescription, and monitoring of exercise relative intensity [130], even if limited by possible poor correspondence to exercise intensity as defined by physiological descriptors of effort intensity domains (i.e. VAT and critical power, see section ‘VO₂ on-kinetics’) [131].

Similar to VO₂R, heart rate reserve (HRR) is defined as the difference between basal and peak heart rate. In healthy sedentary (on both cycle ergometry and treadmill exercise) and in obese adults, the percentage of HRR (%HRR) has been observed also in elite individuals’ fitness [128,129]. The equivalence between exercise intensity and seems to be inversely related to %HRR and %VO₂max, which decreases with increasing fitness [133]; notably, particularly in trained endurance athletes [134], there seems to be a better prediction of %HRR and %VO₂max which decreases with increasing exercise intensity and seems to be inversely related to individuals’ fitness [128,129]. The equivalence between %HRR and %VO₂R has been observed also in elite endurance athletes [134]; notably, particularly in trained individuals, there seems to be a better prediction of %VO₂R from %HRR for running than for arm exercise [135]. Moreover, in patients with type 2 diabetes, %HRR was found to be an excellent descriptor of %VO₂R regardless of the presence of autonomic neuropathy [136]. This finding is consistent with those in patients with previous myocardial infarction both on and off β-blocking therapy [137], in whom an incremental ergometric test without respiratory gas analysis would thus be sufficient for exercise relative intensity assessment. However, in patients with CHF (independently of β-blocking therapy), a considerable uncertainty in prediction of %VO₂R on the basis of %HRR has been observed [138]; carrying out a CPET in individual CHF patient thus seems advisable for exercise relative intensity determination and to avoid training stimulus inadequacy or excessive exercise-related risk.

Regarding minimal aerobic training stimulus intensity, analysis of available studies supports the use of 45%VO₂R as a minimal effective intensity threshold for fit individuals (peakVO₂ > 40 ml/kg per min) and 30%VO₂R for those with a peakVO₂ less than 40 ml/kg per min [139]. Moreover, guidelines recommend a minimal intensity of 40%VO₂R to elicit improvements in aerobic fitness of less fit individuals, 50%VO₂R for the physically active, and up to 85%VO₂R for highly fit individuals [140].

In patients with coronary artery disease, 45%VO₂R is the minimum intensity recommended for improving aerobic fitness [39]; such a relative intensity is higher than that suggested for less fit normal individuals, as most cardiac patients do not reach their maximal effort and thus intensity prescription is based on peakVO₂ and not VO₂max. In any case, in agreement with the lower fitness-lower training stimulus intensity principle [141], relative intensities as low as 23%VO₂R [142], and probably even lower [143], have proved to be effective in CHF patients. From such a low-to-moderate intensity domain, aerobic training stimulus relative intensity can be increased according to individual needs in the high-intensity domain, up to the physiologic limit of aerobic steady-state performance, that is, critical power (see section ‘Critical power’). Once exercise-related risk has been thoroughly assessed, such a training intensity can safely be prescribed also in cardiac patients, both with stable coronary artery disease and preserved left ventricular systolic function or CHF [144,145].

The reported increase in peakVO₂ after a period of aerobic training in normal individuals ranges between 10 and 25%, whereas in cardiac patients it has been found to vary between 7 and 54%, with comparable increases described for VO₂ at VAT [146,147]. However, a great discrepancy exists between different studies as to training-induced peakVO₂ and VO₂ at VAT changes, probably because of differences in study populations, individuals’ or patients’ baseline exercise capacity, and training stimulus intensity and duration. Physiological and performance parameters obtainable from CPET, and useful for aerobic training prescription and monitoring, are summarized in Table 3.

**Table 3 Cardiopulmonary exercise testing physiological and performance parameters useful for aerobic exercise training prescription and monitoring**

<table>
<thead>
<tr>
<th>Intensity</th>
<th>Physiological</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute</td>
<td>VO₂ at VAT</td>
<td>Power at VAT</td>
</tr>
<tr>
<td></td>
<td>HR at VAT</td>
<td>Critical power</td>
</tr>
<tr>
<td></td>
<td>VO₂ at critical power</td>
<td>Peak power</td>
</tr>
<tr>
<td>Relative</td>
<td>%VO₂R at VAT</td>
<td>%HRR at VAT</td>
</tr>
<tr>
<td></td>
<td>%VO₂R at critical power</td>
<td>%VO₂R at critical power</td>
</tr>
<tr>
<td></td>
<td>%HRR at VAT</td>
<td>%HRR at critical power</td>
</tr>
</tbody>
</table>

%HRR, percentage of heart rate reserve; %VO₂R, percentage of VO₂ reserve; HR, heart rate; VAT, ventilatory anaerobic threshold; VO₂, oxygen uptake.
Use of cardiopulmonary exercise testing for the functional evaluation of specific populations

Patients with exercise-induced ischemia

CPET can be useful to detect exercise-induced myocardial ischemia, especially among patients with resting ECG abnormalities. Narrowing of the great epicardial coronary arteries does not let adequate blood flow to the myocardium during effort, which increases the myocardial O₂ need by increasing heart rate, blood pressure, and contractility. Exercise-induced myocardial ischemia is followed by decreased contractility and development of new regional wall-motion abnormalities; these, in turn, can result in decreasing stroke volume and CO and, consequently, reduced oxygen delivery to the periphery above the ischemic threshold. Indeed, patients with exercise-induced silent or symptomatic ischemia have been found to have lower peakVO₂ and oxygen pulse compared with nonischemic controls [148]. Moreover, symptomatic patients had significantly lower values of the same parameters and a higher reduction of left ventricular ejection fraction at peak effort compared with the silent ischemia group [148]. In another study [149], patients with exercise-induced ischemia presented peakVO₂ and oxygen pulse values similar to those of patients with normal perfusion; however, patients with extensive transient perfusion defects had a lower peak oxygen pulse than those with lower exercise-induced ischemia. Decreased VAT VO₂ has also been consistently shown to be related to the presence [148–152] and the extent [153] of myocardial ischemia.

The ischemia-induced reduction in stroke volume can also decrease the VO₂ versus power rise [154] and increase to some extent O₂ deficit values, which in turn could slow the VO₂ off-kinetics. Based on the above considerations, CPET has also been used for myocardial ischemia diagnostic purposes. Belardinelli et al. [155] showed that CPET improves significantly the diagnostic accuracy of standard ECG stress test for detecting exercise-induced myocardial ischemia, demonstrating a flattening of both VO₂ versus power slope and oxygen pulse increase as a consequence of worsening myocardial contraction during ischemia (Fig. 7). Bussottti et al. [150] also demonstrated a significant flattening of VO₂ versus power slope above anaerobic threshold in patients with exercise-induced silent ST-segment depression and presence of great coronary artery narrowing, as compared with patients with ST-segment depression but without coronary artery stenosis. In addition, the presence of a ‘hump’ morphology (i.e. a transient convex bulge at approximately 1 min of the VO₂ off-kinetics) has been shown to identify exercise-induced ischemia with 57% sensitivity and 97% specificity among patients with anterior Q-wave myocardial infarction [156]; such phenomenon could be because of a paradoxical increase of stroke volume after cessation of effort. Therefore, most pathophysiological factors linked to exercise-induced ischemia can be reliably measured by CPET, which should be used extensively for myocardial perfusion evaluation in patients with coronary artery disease, especially in the presence of an uninterpretable ECG during effort. In any case, it must be considered that a significant overlap of data exists among patients with and without ischemia; as a consequence, information derived from CPET should be integrated with other clinical and instrumental descriptors of exercise-induced myocardial ischemia. Changes of CPET parameters induced by myocardial ischemia are summarized in Table 4.

### Table 4 Cardiopulmonary exercise testing parameters in special populations

<table>
<thead>
<tr>
<th>Exercise-induced ischemia</th>
<th>Recent coronary or valvular surgery</th>
<th>Recent or previous heart transplantation</th>
<th>Chronic heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>VO₂ at VAT</td>
<td>N or ↓*</td>
<td>↓ or ↓</td>
<td>↓ or ↓</td>
</tr>
<tr>
<td>Critical power</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Peak VO₂</td>
<td>↓</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
<tr>
<td>VO₂ on-kinetics mean</td>
<td>N or ↓*</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
<tr>
<td>response time</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VO₂ off-kinetics T₁/₂</td>
<td>N or ↓*</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
<tr>
<td>VO₂ uptake efficiency slope</td>
<td>N ?</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
<tr>
<td>VE versus VCO₂ slope</td>
<td>N ?</td>
<td>N or ↑†</td>
<td>↑ or ↑ forever</td>
</tr>
<tr>
<td>External oscillatory ventilation</td>
<td>Absent</td>
<td>Absent</td>
<td>May be present</td>
</tr>
<tr>
<td>Peak cardiac output</td>
<td>↓</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
<tr>
<td>Peak circulatory power</td>
<td>↓</td>
<td>N or ↓</td>
<td>↓ or ↓ forever</td>
</tr>
</tbody>
</table>

*Not enough data available; ↓, reduced or shortened; ↓↓, severely reduced or shortened; ↑↑, increased or prolonged; ↑↑↑, markedly increased or prolonged; N, normal; VAT, ventilatory anaerobic threshold; VCO₂, CO₂ production; VE, ventilation; VO₂, oxygen uptake; ‘Depending on exercise level with respect to ischemic threshold. †Possible ‘hump’ phenomenon. ‡Usually detectable in 10–12% of patients.
**Patients with recent coronary and valvular surgery**

After recent coronary and/or valvular surgery, exercise testing is performed mostly to evaluate exercise tolerance, prescribe individualized training programs, look for residual ischemia and/or exercise-induced arrhythmias, and evaluate prognosis (mostly after coronary artery bypass grafting) [157–160]. Moreover, exercise testing and aerobic training have been recently confirmed to be safe early after heart valve surgery and coronary artery bypass grafting [161]. CPET adds to conventional ergometry the possibility of measuring more precisely patients’ exercise capacity and providing a sound physiological basis for exercise training prescription, in a population of patients with sometimes significantly impaired exercise performance. Indeed, early after cardiac surgery many factors can contribute to a drop of the exercise capacity with respect to the preoperative level: ventilatory impairment (from atelectasis, pleural effusion, and/or phrenic nerve injury), congestive heart failure, reduction of ribs and sternal mobility, anemia, sinus tachycardia, atrial fibrillation (in about 40% of patients), transient postoperative left ventricular dysfunction, and global fatigue [160,162]. Indeed, among patients entering a rehabilitation program after a recent acute cardiac event those with recent coronary artery bypass graft have been found to have the lowest peakVO2 [38].

Exercise tolerance may be even more impaired after heart valve surgery, as physiological hemodynamic conditions are not fully restored by valve replacement or repair. All prostheses are more or less stenotic, and this may result in a hemodynamically significant stenosis during exercise, mostly after mitral valve replacement but probably also in the presence of prosthesis/patient size mismatch after aortic valve replacement [163]. Moreover, heart rate is often higher than after coronary artery bypass grafting (because of absence of systematic β-blocking therapy and/or higher incidence of atrial fibrillation) and no formula allows the calculation of the heart rate at the anaerobic threshold, which is often used as a target during the training sessions. Le Tourneau et al. [164] investigated the functional effects of surgical correction of mitral regurgitation by mitral valve replacement or repair in the absence of cardiac rehabilitation. Patients underwent CPET before and 216 ± 80 days after surgery (i.e. after healing of all transient postoperative complications); surprisingly, mitral regurgitation correction did not lead to an overall improvement of peakVO2 in either the valve repair or replacement group; these results were confirmed by Kim et al. [165]. In contrast, a recent study in early postmitral valve repair patients [166] showed that a CPET performed 21 ± 10 days after surgery allowed to prescribe an exercise aerobic training driven by the measured heart rate at VAT; after completion of the training period, peakVO2, peak power, peak oxygen pulse, and chronotropic reserve improved significantly. These results confirmed those of Douard et al. [167], who observed a significant increase of peakVO2 after a 3-month aerobic training period driven by CPET results in patients having undergone mitral balloon valvuloplasty for mitral stenosis. In summary, early after coronary and especially valvular heart surgery, the spontaneous exercise capacity improvement is weak and CPET allows the prescription of an efficient training program focused on the patient’s physiological limitations. Changes in CPET parameters induced by recent coronary and valvular surgery are summarized in Table 4.

**Patients with chronic heart failure**

A reduced ability to perform aerobic exercise is the hallmark of the CHF pathophysiologic feature [24], related to changes in both peripheral (skeletal muscle, endothelium, regional blood flow, and reflex cardiopulmonary control systems) and central (lung, heart, and Hb content of arterial blood) links of the O2 transport chain from ambient air to the skeletal muscle [168–170]. These changes promote a vicious cycle of deterioration involving catabolic drive and reflex neurohormonal over-activation [170,171], which may lead to disease progression and functional deterioration. As a consequence, in CHF patients peakVO2 is typically reduced with respect to age-matched normal individuals when computed either in absolute (l/min) or weighted terms (ml/kg per min), or as percent of predicted VO2max, and its reduction is proportional to the severity of the syndrome [24,172]. Together with peakVO2, also all the other descriptors of O2 transport and utilization system efficiency are altered. For example, a reduction in the values of VO2 at VAT; a parameter derived from submaximal work rate and therefore independent of patient motivation, has been classically described [26]. However, in the most advanced stages of the syndrome a clear VAT is often not identifiable, particularly in the presence of EOV. Consistent with the above findings, also a reduction in the VO2 versus power slope and a prolongation of both VO2 on-kinetics and off-kinetics in moderate-intensity exercise have been described [19,60] and, in addition to VAT, provide useful submaximal descriptors of O2 transport/utilization system efficiency. Patients with CHF and permanent atrial fibrillation show peakVO2 values even lower than those of CHF patients in sinus rhythm, but with VAT occurring at a higher percentage of peakVO2 [173].

CPET also reveals an increased VE at comparable absolute submaximal levels of effort in CHF patients with respect to age-matched normal individuals [91]. As a consequence, the VE versus VO2 slope is usually increased [174,175] (Fig. 4, lower panel), testifying to a reduced ventilatory efficiency, which may be improved by aerobic training [174]. Such ventilatory inefficiency is further evidenced by a decrease of the OUES with respect to age-matched normal individuals [20,76,81]
(Fig. 4, upper panel). Among the causes of the increased ventilatory response to exercise, a reduced oxygen-diffusing capacity because of an impairment of alveolar-arterial oxygen transfer has been suggested [176], although O₂ transfer is preserved and arterial O₂ desaturation during exercise is rare in otherwise uncomplicated CHF [177]. An increase in dead space VE can be advocated because of a mismatching of VE relative to pulmonary perfusion of the high alveolar VE versus low alveolar perfusion type [91]. Another likely mechanism explaining the excessive exercise VE of CHF patients is an exaggerated ergoreflex response originating in the exercising skeletal muscles during effort [174], in the context of a generalized myopathy with early acidotic response: this may explain also the sympathetic hyper-responsiveness present in this syndrome [175]. In addition, EOV has been described in a variable percentage (20–60%) of CHF patients (Fig. 5), associated with poor exercise capacity and severe prognosis [177,178]. It has been attributed to the interaction of altered hemodynamic and neurohormonal regulatory factors [177,179], even if recent data seem to depict an even more complex pathophysiologic feature [180].

CPET can also be used to monitor the effects of cardiac resynchronization therapy by biventricular pacing on CHF exercise pathophysiology [181], also when upgrading from right ventricular to biventricular pacing [182]. Moreover, CPET has been used for the functional evaluation of CHF patients after left ventricular assist device implantation, demonstrating a significant short-term peakVO₂ improvement [183,184]. Finally, CPET can describe both functional impairment and prognosis of patients with diastolic heart failure [185]. Changes in CPET parameters induced by CHF are summarized in Table 4.

Patients with recent or previous heart transplantation
Despite a successful replacement of the failing heart and a recovery of cardiac function, most heart transplant (HTx) recipients experience a persistent impairment in maximal exercise capacity. Indices of maximal and submaximal aerobic exercise capacity (peakVO₂ and VO₂ at VAT) improve significantly during the first 2 years after HTx, remaining, however, around 60–70% of the age-related and sex-related reference values [186,187].

Several mechanisms, both central and peripheral, may account for this finding. First, surgical-induced cardiac denervation results in a decreased peak heart rate, a delayed heart rate response, and a decreased HRR during incremental exercise (i.e., chronotropic incompetence), which persist for many years after HTx [186]. It has been proposed that the observed chronotropic incompetence, together with cyclosporin-induced diastolic dysfunction, is the major cause of exercise intolerance in HTx recipients; however, recent data obtained in paced and physically trained HTx patients question this hypothesis [188–190]. Second, because of irreversible pretransplant damage of the alveolar-capillary membrane, chronic administration of immunosuppressive drugs, and cytomegalovirus infection, pulmonary diffusion capacity is impaired in most HTx recipients; it is still under debate whether an impaired pulmonary diffusion capacity is a major factor in the limitation of the exercise capacity after HTx [191]. Third, blood flow and oxygen distribution to the skeletal muscles are impaired after HTx. Several authors have demonstrated a decreased capillary density and vascular dysfunction with persistent endothelial dysfunction in the skeletal muscle of HTx patients [192]. It has been shown that improvements in the exercise capacity after exercise training in HTx are highly correlated with improvements in skeletal muscle endothelial function and not to alterations in cardiac or pulmonary function, implying a major role of endothelial function in the observed exercise capacity impairment [193]. Moreover, during the progression of CHF a specific myopathy develops, which persists after HTx and is even worsened by the administration of corticosteroids and cyclosporin, inducing muscle atrophy and a further decrease in oxidative capacity; these detrimental changes result in an inefficient muscle metabolism and a decreased muscle strength [194]. As for endothelial dysfunction, these muscular adaptations can be reversed by exercise training and correlate closely with the observed improvements in exercise capacity [195]. Owing to these muscular metabolic changes, both on-kinetics and off-kinetics of VO₂ during constant-power moderate-intensity exercise are delayed in HTx patients [196,197].

Finally, ventilatory efficiency (expressed both as OUES and VE versus VCO₂ slope) improves during the first years after HTx, remaining, however, impaired and reaching values comparable with those observed in moderate CHF. The increased ventilatory response to exercise may be caused by sustained increases in peripheral chemoreceptor sensitivity and increased muscle metaboreflex activity in response to locally produced metabolites during effort [197,198]. Changes of CPET parameters induced by HTx are summarized in Table 4.

Conclusion
CPET is a methodology now widely available throughout the world and supported by an impressive body of scientific evidence in several different clinical fields. This study emphasizes the opportunities that CPET offers for the functional evaluation of cardiac patients, illustrating the wealth of information obtainable through an experienced use of this powerful tool. The choice of parameters to measure will depend on the specific goals of the functional evaluation in the individual patient, namely, exercise tolerance assessment, training prescription, treatment efficacy evaluation, investigation of
exercise-induced adaptations of the O₂ transport/utilization system (whether of single links or the whole system), etc. However, the full potentialities of CPET in the clinical and research setting still remain largely underused because of inertia of the cardiologic world in the face of a demanding methodology from the cultural standpoint. Strong efforts are needed to promote a more widespread use of CPET in the functional evaluation of cardiac patients.

Acknowledgements
The authors are grateful to Rosemary Allpress for her careful revision of the English manuscript. There are no conflicts of interest.

References
28 Saltin B, Calbet JA. Point: in health and in a normoxic environment, VO2max is limited primarily by cardiac output and locomotor muscle blood flow. J Appl Physiol 2006; 100:744–745.


